Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Operating expense | 2.1M | 24.3% |
| Net Income | -1.8M | 39.7% |
| EBITDA | -1.7M | 37.7% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 9M | 113.3% |
| Total Liabilities | 4M | 11.9% |
| Total Equity | 4.8M | 1190.2% |
| Shares Outstanding | 40M | 0.6% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | -1.9M | 33.5% |
| Cash from financing | 1.5M | 24.1% |
EPS
Financial Highlights for Coeptis Therapeutics in Q3 '24
Operating Expenses for this period were 2.1M, showing a -24.3% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -1.8M, showing a 39.7% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -1.7M, showing a 37.7% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
The company's performance remained stable this quarter with no significant positive or negative changes in the key financial metrics.
